Data from 32 studies on SRS including 1802 patients with GH-secreting pituitary adenomas show median weighted tumor control and biochemical control of disease rates of 95 % and 44 %, respectively, at a median follow-up of 59 months (Table 2) [36, 37, 66, 70, 82, 84–110]. Here, GH1 is linked to pituitary gland adenoma.